Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019

心的外傷後ストレス障害(PTSD)治療薬の世界市場:抗うつ薬、抗不安薬

◆タイトル:Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019
◆商品コード:IRTNTR6225
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年6月24日
◆ページ数:71
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥280,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、心的外傷後ストレス障害(PTSD)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、心的外傷後ストレス障害(PTSD)治療薬の世界市場規模及び予測、製品パイプライン分析、治療薬種類別分析、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About PTSD
PTSD is a psychological condition that develops after a person is exposed to any traumatic event, and it drains a person emotionally. According to the DSM-IV codes found in the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric Association (APA), PTSD is classified under anxiety disorders. PTSD can occur in individuals of any age, irrespective of the gender; its symptoms can develop immediately after a traumatic event or during the course of time. Its symptoms normally include re-experience of the traumatic event, avoidance of the incidents, and abnormal mood swings. Treatments for PTSD include psychological counselling, which help in identifying the cause of the condition and providing counselling to come out of the situation. Medications present in the market help in reducing the symptoms during the course of the treatment.
Technavio’s analysts forecast the global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the global PTSD therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of PTSD. This report includes the segmentation of the market based on geography.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• GlaxoSmithKline
• Pfizer
• Otsuka Pharmaceutical

[Other Prominent Vendors]
• Azevan Pharmaceuticals
• Baylor Research Institute
• Eli Lilly
• Forest Laboratories
• H. Lundbeck
• Humanetics Pharmaceuticals
• Marinus Pharmaceuticals
• Nanotherapeutics
• Neurocrine Biosciences
• Novartis Pharmaceuticals
• Synchroneuron
• Tonix Pharmaceuticals

[Market Driver]
• Growing Number of Accidents and Violence Worldwide
• For a full, detailed list, view our report

[Market Challenge]
• Unavailability of Standard Diagnostic Methods
• For a full, detailed list, view our report

[Market Trend]
• Rise in Public Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Product Profiles
05.1 Paxil/Seroxat
05.2 Zoloft

06.Introduction

07.PTSD Overview
07.1 Understanding the Disorder
07.2 Etiology and Pathogenesis
07.3 Signs and Symptoms
07.3.1 Re-experiencing Symptoms
07.3.2 Avoidance Symptoms
07.3.3 Arousal Symptoms
07.4 Diagnosis
07.5 Management
07.5.1 Psychotherapy
07.5.2 Pharmacotherapy
07.6 Self-Help Treatment of PTSD
07.7 Epidemiology
07.8 Economic Burden

08.Pipeline Analysis
08.1 Information on Pipeline Candidates
08.1.1 Brexpiprazole
08.1.2 Iloperidone
08.1.3 NBI-77860/GSK-561679
08.1.4 At-Ease
08.1.5 PRX-3140
08.1.6 SNC-102
08.1.7 TNX-102 SL
08.1.8 Ganaxolone
08.1.9 SRX251 and SRX246
08.1.10 Doxazosin
08.1.11 pep-EphrinA4

09.Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis

10.Market Segmentation by Class of Drug
10.1 Antidepressant Drugs
10.1.1 SSRIs
10.1.2 SNRIs
10.1.3 Tricyclic Antidepressants
10.1.4 MAO Inhibitors
10.2 Anti-anxiety Drugs
10.2.1 Benzodiazepines
10.2.2 Beta-blockers
10.3 Others
10.3.1 Atypical Antipsychotics
10.3.2 Anticonvulsants
10.3.3 Alpha-1 Receptor Antagonists
10.3.4 Alpha-2 Adrenergic Agonists

11.Geographical Segmentation

12.Buying Criteria

13.Market Growth Drivers

14.Drivers and Their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and Their Impact

19.Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Analysis 2014
19.2.1 Pfizer
19.2.2 GlaxoSmithKline
19.2.3 Otsuka Pharmaceutical
19.3 Other and Future Prominent Vendors

20.Global PTSD Therapeutics Market: Key Takeaways

21.Key Vendor Analysis
21.1 GlaxoSmithKline
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2014
21.1.4 Business Segmentation by Revenue 2013 and 2014
21.1.5 Geographical Segmentation by Revenue 2014
21.1.6 Business Strategy
21.1.7 Recent Developments
21.1.8 SWOT Analysis
21.2 Otsuka Pharmaceutical
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation by Revenue 2014
21.2.4 Business Segmentation by Revenue 2013 and 2014
21.2.5 Geographical Segmentation by Revenue 2014
21.2.6 Business Strategy
21.2.7 Recent Developments
21.2.8 SWOT Analysis
21.3 Pfizer
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2014
21.3.4 Business Segmentation by Revenue 2013 and 2014
21.3.5 Geographical Segmentation by Revenue 2014
21.3.6 Business Strategy
21.3.7 Key Developments
21.3.8 SWOT Analysis

22.Other Reports in This Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Events Leading to PTSD
Exhibit 3: Treatment Options for PTSD
Exhibit 4: Prevalence of PTSD among Women in US
Exhibit 5: Global Prevalence of PTSD by Gender
Exhibit 6: Pipeline Portfolio of PTSD Drugs
Exhibit 7: Global PTSD Therapeutics Market 2014-2019 ($ millions)
Exhibit 8: Segmentation of Global PTSD Therapeutics Market by Class of Drug
Exhibit 9: Segmentation of Global PTSD Therapeutics Market by Region 2014
Exhibit 10: Major Drivers of Global PTSD Therapeutics Market
Exhibit 11: Major Challenges in Global PTSD Therapeutics Market
Exhibit 12: Major Trends in Global PTSD Therapeutics Market
Exhibit 13: Global PTSD Therapeutics Market Analysis 2014
Exhibit 14: Pfizer: YoY Growth and Revenue of Zoloft 2010-2014 ($ millions)
Exhibit 15: Pfizer: Revenue of Zoloft by Region 2010-2014 ($ millions)
Exhibit 16: GlaxoSmithKline: YoY Growth and Revenue of Paxil 2010-2014 ($ millions)
Exhibit 17: GlaxoSmithKline: Revenue of Paxil by Region 2010-2014 ($ millions)
Exhibit 18: Global PTSD Therapeutics Market: Key Takeaways
Exhibit 19: GlaxoSmithKline: Business Segmentation by Revenue 2014
Exhibit 20: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 21: GlaxoSmithKline: Geographical Segmentation by Revenue 2014
Exhibit 22: Otsuka Pharmaceutical: Business Segmentation by Revenue 2014
Exhibit 23: Otsuka Pharmaceutical: Business Segmentation by Revenue 2013 and 2014 ($ millions)
Exhibit 24: Otsuka Pharmaceutical: Geographical Segmentation by Revenue 2014
Exhibit 25: Pfizer: Business Segmentation by Revenue 2014
Exhibit 26: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 27: Pfizer: Geographical Segmentation by Revenue 2014



【掲載企業】

GlaxoSmithKline plc, Pfizer Inc., Otsuka Pharmaceutical Co. Ltd., Abbott Laboratories, Addex Therapeutics, AstraZeneca, Azevan Pharmaceuticals, Baylor Research Institute, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, Eli Lilly, F. Hoffmann-La Roche, Forest Laboratories, H. Lundbeck, Humanetics Pharmaceuticals, Intra-Cellular Therapies, Janssen Pharmaceuticals, Luye Pharma, Marinus Pharmaceuticals, Nanotherapeutics, Naurex, Neurocrine Biosciences, Novartis Pharmaceuticals, Suven, Synchroneuron, Takeda Pharmaceutical, Teva Pharmaceutical, Tonix Pharmaceuticals

【資料のキーワード】

心的外傷後ストレス障害、PTSD治療薬、パイプライン、抗うつ薬、抗不安薬、非定型抗精神病薬、抗痙攣薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[心的外傷後ストレス障害(PTSD)治療薬の世界市場:抗うつ薬、抗不安薬] (Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 / IRTNTR6225)販売に関する免責事項
[心的外傷後ストレス障害(PTSD)治療薬の世界市場:抗うつ薬、抗不安薬] (Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 / IRTNTR6225)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆